Understanding Resistance to EGFR Inhibitors-impact on Future Treatment Strategies

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2010 Jun 17

PMID 20551942

Citations 312

Authors

Deric L Wheeler

Emily F Dunn

Paul M Harari

Affiliations

Soon will be listed here.

Abstract

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis. Following ligand binding, EGFR stimulates downstream cell signaling cascades that influence cell proliferation, apoptosis, migration, survival and complex processes, including angiogenesis and tumorigenesis. EGFR has been strongly implicated in the biology of human epithelial malignancies, with therapeutic applications in cancers of the colon, head and neck, lung, and pancreas. Accordingly, targeting EGFR has been intensely pursued, with the development of a series of promising molecular inhibitors for use in clinical oncology. As is common in cancer therapy, challenges with respect to treatment resistance emerge over time. This situation is certainly true of EGFR inhibitor therapies, where intrinsic and acquired resistance is now well recognized. In this Review, we provide a brief overview regarding the biology of EGFR, preclinical and clinical development of EGFR inhibitors, and molecular mechanisms that underlie the development of treatment resistance. A greater understanding of the mechanisms that lead to EGFR resistance may provide valuable insights to help design new strategies that will enhance the impact of this promising class of inhibitors for the treatment of cancer.

Citing Articles

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.

De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C Front Immunol. 2025; 16:1515748.

PMID: 39995659 PMC: 11847692. DOI: 10.3389/fimmu.2025.1515748.

Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors.

Rajeeve A, Yamuna R, Namboori P Sci Rep. 2025; 15(1):3649.

PMID: 39880831 PMC: 11779874. DOI: 10.1038/s41598-024-83868-5.

Integration of pharmacophore-based virtual screening, molecular docking, ADMET analysis, and MD simulation for targeting EGFR: A comprehensive drug discovery study using commercial databases.

Alanzi A, Moussa A, Alsalhi M, Nawaz T, Ali I PLoS One. 2024; 19(12):e0311527.

PMID: 39652601 PMC: 11627428. DOI: 10.1371/journal.pone.0311527.

From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.

Crossman B, Harmon R, Kostecki K, McDaniel N, Iida M, Corday L J Clin Med. 2024; 13(20).

PMID: 39457986 PMC: 11508784. DOI: 10.3390/jcm13206036.

Ubiquitin-specific protease 10 determines colorectal cancer outcome by modulating epidermal growth factor signaling via inositol polyphosphate-4-phosphatase type IIB.

Kubaichuk K, Seitz T, Bergmann U, Glumoff V, Mennerich D, Kietzmann T Oncogenesis. 2024; 13(1):37.

PMID: 39394169 PMC: 11479595. DOI: 10.1038/s41389-024-00538-x.

References

Libermann T, Nusbaum H, Razon N, Kris R, Lax I, Soreq H . Amplification and overexpression of the EGF receptor gene in primary human glioblastomas. J Cell Sci Suppl. 1985; 3:161-72. DOI: 10.1242/jcs.1985.supplement_3.16. View

Erjala K, Sundvall M, Junttila T, Zhang N, Savisalo M, Mali P . Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2006; 12(13):4103-11. DOI: 10.1158/1078-0432.CCR-05-2404. View

Lynch T, Patel T, Dreisbach L, McCleod M, Heim W, Hermann R . Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010; 28(6):911-7. DOI: 10.1200/JCO.2009.21.9618. View

Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H . A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006; 95(8):998-1004. PMC: 2360715. DOI: 10.1038/sj.bjc.6603393. View

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

Huang S, Bock J, Harari P . Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999; 59(8):1935-40. View

Burtness B, Goldwasser M, Flood W, Mattar B, Forastiere A . Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005; 23(34):8646-54. DOI: 10.1200/JCO.2005.02.4646. View

Klapper L, Glathe S, Vaisman N, Hynes N, ANDREWS G, Sela M . The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A. 1999; 96(9):4995-5000. PMC: 21805. DOI: 10.1073/pnas.96.9.4995. View

10.

Cao H, Lei Z, Bian L, Rao C . Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta. Endocrinology. 1995; 136(7):3163-72. DOI: 10.1210/endo.136.7.7540549. View

11.

Li C, Iida M, Dunn E, Ghia A, Wheeler D . Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 2009; 28(43):3801-13. PMC: 2900381. DOI: 10.1038/onc.2009.234. View

12.

Kawamoto T, Sato J, Le A, Polikoff J, Sato G, Mendelsohn J . Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A. 1983; 80(5):1337-41. PMC: 393592. DOI: 10.1073/pnas.80.5.1337. View

13.

Soria J, Lee H, Lee J, Wang L, Issa J, Kemp B . Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002; 8(5):1178-84. View

14.

Libermann T, Nusbaum H, Razon N, Kris R, Lax I, Soreq H . Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985; 313(5998):144-7. DOI: 10.1038/313144a0. View

15.

Lo H, Xia W, Wei Y, Ali-Seyed M, Huang S, Hung M . Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005; 65(1):338-48. View

16.

Thienelt C, Bunn Jr P, Hanna N, Rosenberg A, Needle M, Long M . Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005; 23(34):8786-93. DOI: 10.1200/JCO.2005.03.1997. View

17.

Xia W, Wei Y, Du Y, Liu J, Chang B, Yu Y . Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog. 2008; 48(7):610-7. PMC: 2718429. DOI: 10.1002/mc.20504. View

18.

Chakravarti A, Loeffler J, Dyson N . Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002; 62(1):200-7. View

19.

Zhou B, Peyton M, He B, Liu C, Girard L, Caudler E . Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006; 10(1):39-50. PMC: 4451119. DOI: 10.1016/j.ccr.2006.05.024. View

20.

Biscardi J, Maa M, Tice D, Cox M, Leu T, Parsons S . c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem. 1999; 274(12):8335-43. DOI: 10.1074/jbc.274.12.8335. View